Use no more than once or twice per week, as regular use can lead to dependency and actually worsen constipation over time
GLP-1 medicines are not approved for managing period, hot-flash, or energy symptoms, and a changed period, new hot flashes, or persistent fatigue should be discussed with your doctor or licensed clinician especially if symptoms are severe, sudden, or could indicate pregnancy or another condition
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
To better accelerate your GLP-1 new drug research and development, GenScript is now offering GLP-1 Receptor Agonist Services
The GLP-1 receptor (GLP-1R), which mediates the biological effects of the hormone with relevance for and beyond CVD, is present across many organs and tissues in humans (Figure 1)
Clinical researchers observed that participants on the highest Retatrutide dose lost nearly 10 percentage points more body weight compared to those on the leading GLP-1 only medication